Literature DB >> 1317801

In vitro activity of azithromycin and tetracycline against 358 clinical isolates of Brucella melitensis.

R Landínez1, J Liñares, E Loza, J Martínez-Beltrán, R Martín, F Baquero.   

Abstract

The in vitro activity of azithromycin against human pathogenic strains of Brucella melitensis was tested at three centres and compared to that of tetracycline, the standard antibiotic currently used for the treatment of human brucellosis. MIC determination was carried out. Tested concentration ranges for both azithromycin and tetracycline were between 0.03 and 16 micrograms/ml. Brucella melitensis biotype 1, strain M16 was employed as a control microorganism. A total of 358 Brucella melitensis strains from human blood cultures were tested. MIC90 (micrograms/ml) values ranged from 0.5 to 1.00 for azithromycin and were 0.25 for tetracycline. It was concluded that there was little difference in the sensitivity of pathogenic Brucella melitensis to azithromycin and tetracycline isolated from three different regions in Spain. These results encourage further investigations on the possible therapeutic role of azithromycin in brucellosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317801     DOI: 10.1007/bf02098096

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  4 in total

1.  Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study.

Authors:  G Acocella; A Bertrand; J Beytout; J B Durrande; J A Garcia Rodriguez; J Kosmidis; M Micoud; M Rey; M Rodriguez Zapata; J Roux
Journal:  J Antimicrob Chemother       Date:  1989-03       Impact factor: 5.790

2.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

3.  In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection.

Authors:  R P Gladue; G M Bright; R E Isaacson; M F Newborg
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

4.  Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosis.

Authors:  J Ariza; F Gudiol; R Pallarés; G Rufí; P Fernández-Viladrich
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

  4 in total
  5 in total

1.  Broth microdilution susceptibility testing of Brucella species: quality control limits for ten antimicrobial agents against three standard quality control strains.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

Review 2.  Recognition and optimum treatment of brucellosis.

Authors:  J Solera; E Martínez-Alfaro; A Espinosa
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

3.  In vitro activities of new macrolides and rifapentine against Brucella spp.

Authors:  J A García-Rodríguez; J L Muñoz Bellido; M J Fresnadillo; I Trujillano
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 4.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

5.  Epidemiologically characteristics of human brucellosis and antimicrobial susceptibility pattern of Brucella melitensis in Hinggan League of the Inner Mongolia Autonomous Region, China.

Authors:  Hai-Tao Yuan; Cheng-Ling Wang; Li-Na Liu; Dan Wang; Dan Li; Zhen-Jun Li; Zhi-Guo Liu
Journal:  Infect Dis Poverty       Date:  2020-06-29       Impact factor: 4.520

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.